Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling

Clicks: 19
ID: 329098
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #147 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives To evaluate the association between avacopan (AVA) use and recurrent relapse and severe infection in patients with ANCA-associated vasculitis, with particular attention to time-varying treatment and glucocorticoid exposure. Methods In this multicentre retrospective cohort study, AVA use was modelled as a time-varying exposure. Stabilized inverse probability of treatment weighting was used to adjust for baseline differences. Recurrent relapse and severe infection, defined as an infection requiring hospitalisation, were analysed using time-dependent Cox proportional hazards models based on the Andersen–Gill formulation. Exploratory models additionally incorporated time-varying and cumulative prednisolone exposure. Results A total of 387 patients were included, of whom 52 received AVA and 335 did not. AVA exposure was associated with a lower estimated risk of severe infection (adjusted HR 0.22, 95% CI 0.07–0.68; P = 0.008), whereas no statistically significant difference in recurrent relapse risk was observed. AVA use was also associated with lower prednisolone exposure over time. This association with severe infection remained directionally consistent in glucocorticoid-adjusted models, although its magnitude varied depending on model specification. Conclusion In this multicentre real-world cohort, AVA exposure was associated with a lower estimated risk of severe infection and reduced glucocorticoid exposure, whereas no statistically significant reduction in recurrent relapse risk was observed. These findings suggest that an AVA-containing treatment strategy may be associated with improved infection-related outcomes in routine practice, although the observational design precludes causal inference.
Reference Key
openalex_W7213553503 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tsuneyasu Yoshida, Ryosuke Hiwa, Mikihito Shoji, Atsushi Manabe, Keiichiro Kadoba, Tomoki Taniguchi, Ryosuke Tsuge, Shogo Matsuda, Takuya Kotani, Ayana Okazaki, Yuichi Masuda, Muneyuki Hatta, Mayu Shiomi, Naoko Ito, Youhei Fujiki, Hirofumi Miyake, Ryu Watanabe, Motomu Hashimoto, Akio Morinobu
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag517
URL
https://doi.org/10.1093/rheumatology/keag517
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.